By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.
ContinueThis website is intended only for healthcare professionals outside the US, UK and Australia.
Roche COVID-19 Response | For medical/scientific information related to COVID-19, visit medinfo.roche.com
Assessment of the efficacy and safety of pirfenidone (2403 mg/day) versus placebo over 24 weeks in patients diagnosed with progressive fibrotic uILD.
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
Receive this presentation and more content via email
Also In Respiratory Disease:
Also In Respiratory Disease:
Also In Respiratory Disease: